 Daclatasvir is a recently approved anti-HCV agent that is a CYP3A4 substrate but does not affect CYP450 itself. It is also a moderate inhibitor of various membrane transporters such as organic anion-transporting polypeptide OATP1B1, P-glycoprotein P-gP, and organic cation transporters OCT2. 